Bristol-Myers Squibb: Heart Failure trials

The registry lists 24 Heart Failure studies with Bristol-Myers Squibb as lead sponsor. 1 are open to participants now and 7 have results posted.

Phase 1 10Phase 2 9Phase 3 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)RecruitingNCT05489705
• A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnTCompletedNCT04766892Phase 2Results posted
• Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart FailureCompletedNCT04318093Phase 2Results posted
• An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop DiureticCompletedNCT03730961Phase 2Results posted
• A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic FunctionCompletedNCT03357731Phase 2Results posted
• Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart FailureCompletedNCT03016325Phase 2Results posted
• A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart FailureCompletedNCT02157506Phase 2Results posted
• Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)CompletedNCT00095238Phase 3Results posted
• Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)Active, not recruitingNCT06122779Phase 2
• A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart FailureCompletedNCT05952089Phase 1
• A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy ParticipantsCompletedNCT03891108Phase 1
• An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired ParticipantsCompletedNCT03634969Phase 1
• Study of the Sudden Heart Failure Participant Population in the USWithdrawnNCT03566264
• An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver FunctionCompletedNCT03515980Phase 1
• A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF)Status unknownNCT03515655
• Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart FailureCompletedNCT03508271
• A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney FunctionCompletedNCT03332186Phase 1
• A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection FractionTerminatedNCT03281122Phase 1
• Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male ParticipantsCompletedNCT03210909Phase 1
• Study With Healthy Japanese and Non-Asian Participants With BMS-986231CompletedNCT02932969Phase 1
• A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy VolunteersCompletedNCT02819271Phase 1
• An Observational Study of the Functional Capacity of Heart FailureCompletedNCT02350114Not applicable
• A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart FailureCompletedNCT01096043Phase 2
• Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart FailureCompletedNCT01092325Phase 1/2